The traditional Design-Make-Test-Analyse (DMTA) framework forces researchers into rigid, sequential paths that often prioritize IT compliance over actual scientific progress. In its paper, The Billion-Dollar Bottleneck: Why CMC Is Strangling the Biopharma Pipeline, Zifo argues that this structure causes a critical loss of decision-making knowledge. As data moves between systems, teams, and lifecycle stages, it frequently detaches from its original samples, methods, and process conditions, forcing scientists to spend valuable time reconstructing experimental histories.
Zifo Challenges Rigid Biopharma Workflow Models
Biopharma companies are trapped in a "DMTA doom loop," a cycle of disconnected experiments and manual data reconstruction that stifles innovation. According to a new position paper from Zifo, the industry must pivot from linear, sequential processes toward an agile, interconnected network that preserves scientific context.
Zifo contends that simply digitizing existing paper-based workflows is insufficient, as it often creates a faster version of the same fragmented process. Instead, the firm advocates for an orchestration layer that connects scientific activity across existing systems of record. This approach centers on the scientist's experience, utilizing modular, adaptable components rather than monolithic platforms. By integrating governed Scientific Language Models and prioritizing targeted, high-value implementations, organizations can move away from siloed handoffs. This shift allows researchers to jump between process stages as biological problems demand, transforming the goal of the laboratory from merely completing experiments to compounding organizational knowledge.
Comments (0)
No comments yet. Be the first!